PE6572018A1 - immunogenic compositions comprising capsular saccharide antigens conjugated kits comprising them and their uses - Google Patents

immunogenic compositions comprising capsular saccharide antigens conjugated kits comprising them and their uses

Info

Publication number
PE6572018A1
PE6572018A1 PE2018000092A PE0000922018A PE6572018A1 PE 6572018 A1 PE6572018 A1 PE 6572018A1 PE 2018000092 A PE2018000092 A PE 2018000092A PE 0000922018 A PE0000922018 A PE 0000922018A PE 6572018 A1 PE6572018 A1 PE 6572018A1
Authority
PE
Peru
Prior art keywords
immunogenic compositions
kits
uses
capsular saccharide
saccharide antigens
Prior art date
Application number
PE2018000092A
Other languages
Spanish (es)
Inventor
Wendy Jo Watson
Martin-Montalvo Luis Pascual Jodar
Raul Enrique Isturiz
Ralf Rene Reinert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201562194965P priority Critical
Application filed by Pfizer filed Critical Pfizer
Publication of PE6572018A1 publication Critical patent/PE6572018A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Abstract

La presente invencion se refiere a nuevas composiciones inmunogenas que comprenden antigenos de sacarido capsular de Streptococcus pneumoniae conjugados (glucoconjugados), kits que comprenden tales composiciones inmunogenas y sus usos. The present invention relates to novel immunogenic compositions comprising capsular saccharide antigens from Streptococcus pneumoniae conjugated (glycoconjugates), kits comprising such immunogenic compositions and their uses. En general, las composiciones inmunogenas de la presente invencion comprenden al menos un glucoconjugado de un serotipo de S. pneumoniae no encontrado en PREVNAR®, SYNFLORIX® y/o PREVNAR 13®. In general, the immunogenic compositions of the present invention comprise at least one glycoconjugate one serotype of S. pneumoniae not found PREVNAR ®, Synflorix and / or PREVNAR 13®. La invencion tambien se refiere a la vacunacion de sujetos humanos, en particular, ninos y personas mayores, contra infecciones neumococicas usando tales composiciones inmunogenas novedosas. The invention also relates to vaccinating human subjects, particularly children and the elderly, against pneumococcal infections using such novel immunogenic compositions.
PE2018000092A 2015-07-21 2016-07-18 immunogenic compositions comprising capsular saccharide antigens conjugated kits comprising them and their uses PE6572018A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201562194965P true 2015-07-21 2015-07-21

Publications (1)

Publication Number Publication Date
PE6572018A1 true PE6572018A1 (en) 2018-04-17

Family

ID=56507633

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000092A PE6572018A1 (en) 2015-07-21 2016-07-18 immunogenic compositions comprising capsular saccharide antigens conjugated kits comprising them and their uses

Country Status (16)

Country Link
US (2) US10124050B2 (en)
EP (1) EP3325008A1 (en)
JP (1) JP2018524380A (en)
KR (1) KR20180030175A (en)
CN (1) CN108367063A (en)
AR (1) AR105402A1 (en)
AU (1) AU2016295566B2 (en)
BR (1) BR112018000087A2 (en)
CA (1) CA2936378A1 (en)
CO (1) CO2018000503A2 (en)
IL (1) IL256645D0 (en)
MX (1) MX2018000867A (en)
PE (1) PE6572018A1 (en)
PH (1) PH12018500037A1 (en)
TW (2) TW201718005A (en)
WO (1) WO2017013548A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105934251A (en) * 2014-01-21 2016-09-07 辉瑞大药厂 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
PE6572018A1 (en) * 2015-07-21 2018-04-17 Pfizer immunogenic compositions comprising capsular saccharide antigens conjugated kits comprising them and their uses
WO2019050814A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050813A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050815A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050816A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019070994A1 (en) * 2017-10-04 2019-04-11 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag Synthetic antigenic, process for their production and their use
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use for the development of synthetic vaccines.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren Protein D - an IgD-binding protein FROM Haemophilus influenzae, and anvaendning this Foer analysis, vaccines and uppreningsaendamaal
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Fiber hemagglutinin of Bordetella pertussis as carrier for conjugated vaccine.
ES2204900T3 (en) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine inmuinogena structure dual vector.
IT1262896B (en) 1992-03-06 1996-07-22 Compounds conjugates formed by heat shock proteins (hsp) poly- and oligo-saccharides, their use for the production of vaccines.
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
CZ282235B6 (en) 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) Inoculation substance, process of its preparation and use
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69434079D1 (en) 1993-03-05 2004-11-25 Wyeth Corp Plasmid for the production of CRM protein and diphtheria toxin
DE69428136D1 (en) 1993-03-23 2001-10-04 Smithkline Beecham Biolog 3-0 Deazylierte monophosphoryl lipid A containing vaccine compositions
DE69628418T2 (en) 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Preparation of immunogenic constructs using of soluble carbohydrates which have been activated by organic reagents cyanylierungs
JP3828145B2 (en) 1993-09-22 2006-10-04 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン Activation method of soluble carbohydrates using new cyanide reagents for the preparation of an immunogenic construct
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
ES2267100T5 (en) 1994-07-15 2011-04-08 Coley Pharmaceutical Group, Inc. Immunomodulatory oligonucleotides.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
CA2301575C (en) 1997-05-20 2003-12-23 Heather L. Davis Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PT1126876E (en) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Adjuvant systems and vaccines
DE69940439D1 (en) 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteins and immunogenic fragments for Vaccines
KR100891398B1 (en) 1998-12-23 2009-04-02 아이디 바이오메디칼 코포레이션 Novel Streptococcus antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DE60044236D1 (en) 1999-02-17 2010-06-02 Csl Ltd Immunogenic complex and methods with respect to these
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
PT1162999E (en) 1999-03-19 2007-02-28 Glaxosmithkline Biolog Sa Vaccine against streptococcus pneumoniae
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CN1227030C (en) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CZ20021045A3 (en) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Auxiliary preparation
CO5200837A1 (en) 1999-09-24 2002-09-27 Smithkline Beecham Corp vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NZ553554A (en) 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
CA2812817C (en) 2003-03-13 2016-12-20 Glaxosmithkline Biologicals S.A. Method of detoxification of pneumolysin
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
KR100958505B1 (en) 2004-07-18 2010-05-17 씨에스엘 리미티드 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104815327A (en) 2005-04-08 2015-08-05 惠氏有限责任公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2007012337A (en) 2005-04-08 2007-11-21 Wyeth Corp Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation.
UA95237C2 (en) * 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Immunogenic composition
KR101365001B1 (en) * 2005-12-22 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. Pneumococcal polysaccharide conjugate vaccine
ES2346929T3 (en) 2006-10-10 2010-10-21 Wyeth Llc Improved methods for separation of polysaccharides of Streptococcus pneumoniae type 3 procedures.
MX2009010221A (en) 2007-03-23 2009-10-19 Wyeth Corp Shortened purification process for the production of capsularstreptococcus pneumoniae polysaccharides.
CN105267974A (en) 2007-06-20 2016-01-27 辉瑞爱尔兰制药公司 Modified polysaccharides for conjugate vaccines
CN101784282B (en) * 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
AU2010243285B2 (en) 2009-04-30 2013-06-06 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
KR101774062B1 (en) * 2009-06-22 2017-09-01 와이어쓰 엘엘씨 Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
MX2013006539A (en) 2010-12-10 2013-07-22 Merck Sharp & Dohme Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions.
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
JP2015510872A (en) * 2012-03-07 2015-04-13 ノバルティス アーゲー Enhanced formulation of Streptococcuspneumoniae antigen
SI2885007T1 (en) * 2012-08-16 2018-12-31 Pfizer Inc. Glycoconjugation processes and compositions
CN103656631B (en) * 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 Multivalent pneumococcal capsular polysaccharide - protein conjugate composition and preparation method
CN104968366B (en) * 2012-10-17 2017-12-01 葛兰素史密丝克莱恩生物有限公司 Comprising one or more S. pneumoniae capsular saccharide conjugate and E contain proteins from Haemophilus influenzae and / or immunogenic composition of protein components PilA
GB201218660D0 (en) * 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075201A (en) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
US20150328328A1 (en) 2012-12-20 2015-11-19 Pfizer Inc. Glycoconjugation process
ITMI20130142A1 (en) 2013-01-31 2014-08-01 Biosynth Srl glycoconjugate vaccines comprising units' base of a molecular construct expressing multiple embedded epitopes
US20150079132A1 (en) * 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
CN103495161B (en) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 A kind of mixture and preparation method thereof of polynary pneumococcal capsular polysaccharide-protein conjugate
EP3096785A2 (en) * 2014-01-21 2016-11-30 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3096786A2 (en) * 2014-01-21 2016-11-30 Pfizer Inc Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
CN105934251A (en) * 2014-01-21 2016-09-07 辉瑞大药厂 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
CA2939416A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
MX2017009308A (en) 2015-01-15 2017-11-08 Pfizer Immunogenic compositions for use in pneumococcal vaccines.
WO2016168324A1 (en) * 2015-04-13 2016-10-20 University Of Maryland, Baltimore Compositions and methods for producing bacterial conjugate vaccines
PE6572018A1 (en) * 2015-07-21 2018-04-17 Pfizer immunogenic compositions comprising capsular saccharide antigens conjugated kits comprising them and their uses
US20180099039A1 (en) * 2016-10-06 2018-04-12 Pfizer Inc. Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof

Also Published As

Publication number Publication date
CN108367063A (en) 2018-08-03
PH12018500037A1 (en) 2018-07-09
US10124050B2 (en) 2018-11-13
KR20180030175A (en) 2018-03-21
WO2017013548A1 (en) 2017-01-26
AR105402A1 (en) 2017-09-27
CO2018000503A2 (en) 2018-06-12
TW201822814A (en) 2018-07-01
AU2016295566B2 (en) 2019-06-20
CA2936378A1 (en) 2017-01-21
BR112018000087A2 (en) 2018-09-04
JP2018524380A (en) 2018-08-30
MX2018000867A (en) 2018-05-15
AU2016295566A1 (en) 2018-01-18
TW201718005A (en) 2017-06-01
US20170021006A1 (en) 2017-01-26
IL256645D0 (en) 2018-02-28
EP3325008A1 (en) 2018-05-30
US20190070282A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
AR058592A1 (en) Vaccine
BR0009166A (en) Vaccine
WO2009000825A3 (en) Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
CO6680687A2 (en) Immunoglobulins dual variable domain capable of binding yl 1 beta and IL-17, pharmaceutical compositions and conjugates binding protein thereof
DOP2009000269A (en) Humanized antibodies against globulomero ab (20-42) and their uses
BR112012008833A2 (en) dual variable domain immunoglobulin and uses thereof
BRPI0710210A2 (en) immunogenic composition, vaccine, methods to prepare the vaccine, and for preventing or treating staphylococcal infection, use of the immunogenic composition, and process for conjugating capsular polysaccharide or oligassacarìdeo
BR112013000630A2 (en) dual variable domain immunoglobulin and uses thereof.
BRPI0407101A (en) Meningococcal mucosal vaccines
ES2152421T3 (en) Pneumococcal polysaccharide conjugate vaccines recombinant pneumolysin-for immunization against pneumococcal infections.
BRPI0608877A2 (en) immunogenic composiÇço rotavirus liquid, use of an antigen rotavirus a aÇécar and a carboxylate, and a human live attenuated rotavirus, and methods for prevenÇço or treatment of disease associated with rotavirus in humans, and the preparaÇço a composiÇço rotavirus liquid
TW200722101A (en) Novel composition
KR20160095006A (en) Synergistic bacterial compositions and methods of production and use thereof
BRPI0609362A2 (en) recombinant adenovirus vector, recombinant adenovirus, immunogenic composition and method for the production of said immunogenic composition
BR112013006396A2 (en) immunogenic compositions
ECSP088778A (en) Formulation of a human monoclonal anti-IGF1 R
JP2014218516A5 (en)
EA200801935A1 (en) conjugate vaccines
CO6382140A2 (en) Vaccine compositions comprising a protein factor binding h mutated
BRPI0920460A2 (en) torsion shaft with variable wall thickness along
BR112018000862A2 (en) Vaccine compositions
PE6732018A1 (en) Cancer treatment by manipulation of the commensal microflora
BR112015013695A2 (en) pharmaceutical composition, and methods for treatment and prevention of HIV infection
AR096113A1 (en) Polypeptides soluble f premelting of respiratory syncytial virus (RSV) and stabilized
BR112015014458A2 (en) mannose derivatives for the treatment of bacterial infections